Immune-Oncology Biomarkers of Response & Resistance
Utilizing Sonrai Discovery, we dive into the analysis of data from four melanoma immunotherapy clinical trials, focusing on 256 patients undergoing treatment with anti-PD-L1 or anti-CTLA-4 therapies. By integrating RNA Sequencing and Whole Exome Sequencing data, Sonrai Discovery quickly uncovers critical biomarkers that predict how patients will respond to treatment and identify potential resistance mechanisms. Sonrai Discovery offers a deeper understanding of tumor immune activity, paving the way for more personalized and effective cancer therapies.
Discover how Sonrai Cloud transformed our clients data analysis and reporting for their immunotherapy clinical trial. Click to explore the case study and learn more.